Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Primary Central Nervous System Lymphoma: early-phase trial registry
9 of 13 indexed Primary Central Nervous System Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 9 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Primary Central Nervous System Lymphoma: 13 US clinical trials tracked, 9 recruiting.
Primary Central Nervous System Lymphoma is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is Dana-Farber Cancer Institute, running 2 of these trials.
Enrollment posture brief
Registry condition primary-central-nervous-system-lymphoma
OPEN 9 | RECR 69% | LATE 0 | EARLY 13 | RANK #1315 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Ankle Fractures (69% recruiting · 13 trials)
Primary Central Nervous System Lymphoma lists 9 open slots (69% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Primary Central Nervous System Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Primary Central Nervous System Lymphoma is recruiting above its size-band peers.
9 of 13 indexed trials (69.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Primary Central Nervous System Lymphoma research.
Dana-Farber Cancer Institute accounts for 2 of 13 trials (15.4%). 11 distinct sponsors appear on at least one study for this condition label.
-
Most Primary Central Nervous System Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 26 among the 13 trials that report a genuine target (sentinel values excluded). 12 of those (92.3%) plan for fewer than 100 participants.
-
Primary Central Nervous System Lymphoma research is mostly interventional.
13 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
National Cancer Institute (NCI)
NCT02203526
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Dana-Farber Cancer Institute
NCT04421560
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
James Rubenstein
NCT05351593
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
Providence Health & Services
NCT06175000
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
Memorial Sloan Kettering Cancer Center
NCT07082868
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
Lakshmi Nayak, MD
NCT04906096
Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma
City of Hope Medical Center
NCT06922604
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Baptist Health South Florida
NCT05681195
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
Dana-Farber Cancer Institute
NCT06475235
Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma
Washington University School of Medicine
NCT04462328
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Celgene
NCT01421524
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
TG Therapeutics
NCT01647971
Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Memorial Sloan Kettering Cancer Center
NCT02301364
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Primary Central Nervous System Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Primary Central Nervous System Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Primary Central Nervous System Lymphoma page
13 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Primary Central Nervous System Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Dana-Farber Cancer Institute sponsors the most Primary Central Nervous System Lymphoma trials on record, review their full trial history before evaluating a specific study. See Dana-Farber Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Central Nervous System Lymphoma condition card totals 13 registered trials; most-linked intervention Rituximab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.